Latest Kaiser Health News Stories
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Alice Ollstein of Politico talk about how health issues will play in midterm elections, the Trump administration’s move that could penalize legal immigrants who use government aid programs, and other topics. Due to technical difficulties, the original discussion taped Sept. 27 at the 2018 Texas Tribune Festival could not be broadcast, so the panelists reconvened from Austin and Washington on Sept. 28.
The protection is a win for people who get their needed, legitimate drugs from overseas.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren’t proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
Federal officials are allowing the private insurance plans to use “step therapy” for drugs administered by doctors. In step therapy, patients must first use cheaper drugs to see if they work before receiving more expensive options.
Embattled drugmaker Purdue Pharma defends OxyContin as some insurers are dropping the drug in favor of other abuse-deterrent opioid painkillers.
As HHS decided to cut $1.6 billion in drug payments to hospitals, it weighed thousands of comments generated by a pharmaceutical-funded advocacy group.
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Post-9/11, Giuliani Partners helped craft a plan that put a halt to a probe into Purdue’s marketing of OxyContin.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico answer listeners’ questions about health policy and politics.
Through a widely circulated brochure and a videotape of testimonials, the maker of OxyContin stressed patients’ right to opioid treatment for pain.
The opioid epidemic has increased the number of donated organs. Until recently, though, organs from donors who died of drug overdoses were often discarded because an estimated 30 percent of them were infected with hepatitis C.
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
A study published Thursday shows that doctors, dentists and other medical providers cut overall opioid dosages by nearly 10 percent after receiving notification of a death from a medical examiner and information on safe prescribing.